Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Davide Mascolo
Institutions:
Instituto Nazionale Tumori Regina Elena,
Sapienza University of Rome
Observed institutions:
Instituto Nazionale Tumori Regina Elena,
Sapienza University of Rome
ORCID:
0009-0009-8425-1619
Observed ORCID:
0009-0009-8425-1619
OpenAlex ID:
A5093740439
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer
2026
·
Giulia Schiavoni
, Antonella Palmese
, et al.
·
Molecular Oncology
·
3
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
·
Clinical Cancer Research
·
1
Multi-layer network modelling of genomic and transcriptomic data to investigate the response to checkpoint inhibitors in NSCLC
2023
·
Davide Mascolo
, Lorenzo Farina
, et al.
·
IEEE International Conference on Bioinformatics and Biomedicine (BIBM)
·
1
Supplementary Table S1 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S9 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S11 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S16 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S8 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S15 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S6 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S3 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Table S2 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Table S3 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S1 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Table S4 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S13 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S18 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S4 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Table S6 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S2 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Data from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S7 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S17 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S10 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S12 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Show more works
View as search
Works count:
31
Citation count:
5
H-index:
1
I10-index:
Year
Topic
Type